Machine Learning Analysis Identified NNMT As a Potential Therapeutic Target for Hepatocellular Carcinoma Based on PCD-related Genes

Overview

Journal Sci Rep

Specialty Science

Date 2025 Mar 3

PMID 40032894

Authors

Fuqun Wei

PeiShu Huang

Bing Zhang

Rui Guo

Xiang You

Zhong Wu Chen

Yiping Chen

Affiliations

Soon will be listed here.

Abstract

Programmed cell death (PCD) plays a critical role in cancer biology, influencing tumor progression and treatment response. This study aims to investigate the role of PCD-related genes in hepatocellular carcinoma (HCC), identifying potential prognostic biomarkers and therapeutic targets to enhance patient outcomes. Data from the GEO, TCGA, and ICGC databases were analyzed to identify differentially expressed genes associated with PCD in HCC. A cell death signature (CDS) model was constructed based on seven key PCD genes using machine learning techniques, including Random Survival Forest and Cox regression models. The model was validated across multiple cohorts to evaluate its predictive accuracy for clinical outcomes, immune infiltration, and therapeutic response, and further validation of the relationship between NNMT overexpression and clinical prognosis using tumor tissue microarray data, and in vitro experiments to confirm the impact of NNMT overexpression on cell proliferation and apoptosis. A total of 183 differentially expressed genes were identified, leading to the construction of a CDS model that incorporates seven key PCD-related genes (PRGs). The CDS showed significant associations with overall survival, immune cell infiltration, and therapeutic response in HCC patients. High CDS scores were linked to poorer prognosis, increased tumor immune exclusion, and decreased efficacy of immunotherapy and conventional treatments. The model demonstrated strong predictive performance across independent validation cohorts, underscoring its potential as a valuable prognostic tool. Additionally, NNMT overexpression promotes HepG2 proliferation, inhibits apoptosis, and correlates with poor prognosis in HCC patients. This study established a prognostic model for HCC based on PCD, and the CDS holds promise as a powerful tool for personalized risk assessment and treatment planning in HCC. Moreover, the model gene NNMT may serve as a potential therapeutic target for HCC.

References

Ye Y, Zhang S, Jiang Y, Huang Y, Wang G, Zhang M . Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer. Sci Rep. 2023; 13(1):21565. PMC: 10700659. DOI: 10.1038/s41598-023-48653-w. View

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

Xiao S, Hu J, Hu N, Sheng L, Rao H, Zheng G . Identification of a Novel Epithelial-to-mesenchymal-related Gene Signature in Predicting Survival of Patients with Hepatocellular Carcinoma. Comb Chem High Throughput Screen. 2021; 25(8):1254-1270. DOI: 10.2174/1386207324666210303093629. View

Deng M, Sun S, Zhao R, Guan R, Zhang Z, Li S . The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Mol Med. 2022; 28(1):16. PMC: 8818170. DOI: 10.1186/s10020-022-00445-0. View

Geeleher P, Cox N, Huang R . pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014; 9(9):e107468. PMC: 4167990. DOI: 10.1371/journal.pone.0107468. View

Zhou Y, Gao W, Xu Y, Wang J, Wang X, Shan L . Implications of different cell death patterns for prognosis and immunity in lung adenocarcinoma. NPJ Precis Oncol. 2023; 7(1):121. PMC: 10651893. DOI: 10.1038/s41698-023-00456-y. View

Liu H, Zhang W, Zhang Y, Adegboro A, Fasoranti D, Dai L . Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection. Comput Struct Biotechnol J. 2024; 23:2798-2810. PMC: 11269309. DOI: 10.1016/j.csbj.2024.06.035. View

Wang S, Wang R, Hu D, Zhang C, Cao P, Huang J . Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy. NPJ Precis Oncol. 2024; 8(1):49. PMC: 10897292. DOI: 10.1038/s41698-024-00538-5. View

10.

Liu L, Wu L, Shan D, Han B . Characterization and clinical relevance of PDGFRA pathway copy number variation gains across human cancers. Mol Genet Genomics. 2022; 297(2):561-571. PMC: 8960564. DOI: 10.1007/s00438-022-01860-y. View

11.

Bian G, Cao J, Li W, Huang D, Ding X, Zang X . Identification and Validation of a Cancer-Testis Antigen-Related Signature to Predict the Prognosis in Stomach Adenocarcinoma. J Cancer. 2024; 15(11):3596-3611. PMC: 11134429. DOI: 10.7150/jca.91842. View

12.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

13.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

14.

Hu W, Shi Y, Han T, Liu C, Cao X, Shi G . A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma. Front Genet. 2022; 13:879299. PMC: 9110819. DOI: 10.3389/fgene.2022.879299. View

15.

Hu F, Liu C, Liu L, Zhang Q, Guo A . Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa176. View

16.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

17.

Palicelli A, Croci S, Bisagni A, Zanetti E, de Biase D, Melli B . What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. Int J Mol Sci. 2021; 22(22). PMC: 8618001. DOI: 10.3390/ijms222212330. View

18.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

19.

Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K . Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019; 16(12):1289-1296. PMC: 6884693. DOI: 10.1038/s41592-019-0619-0. View

20.

Hao Y, Hao S, Andersen-Nissen E, Mauck 3rd W, Zheng S, Butler A . Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13):3573-3587.e29. PMC: 8238499. DOI: 10.1016/j.cell.2021.04.048. View